{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:53:30Z","timestamp":1771880010139,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T00:00:00Z","timestamp":1192147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rotigotine is a new, non\u2010ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine, ropinirole, or placebo. The titration period was up to 13 weeks, and there was a minimum dose\u2010maintenance period of 24 weeks for ropinirole and 33 weeks for rotigotine. The primary endpoint was the proportion of patients with a minimum of 20% decrease in the combined Unified Parkinson's Disease Rating Scale Part II and Part III scores. The responder rate in the rotigotine group was significantly higher than in the placebo group (52% vs. 30%, <jats:italic>P<\/jats:italic> &lt; 0.0001). Transdermal rotigotine at doses \u22648 mg\/24 h did not show noninferiority to ropinirole at doses \u226424 mg\/day. In a post\u2010hoc subgroup analysis, rotigotine \u22648 mg\/24 hours had a similar efficacy to ropinirole at doses \u226412 mg\/day. The rotigotine transdermal patch was well tolerated. The most common adverse events were application\u2010site reactions, nausea, and somnolence. Application\u2010site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease.<\/jats:p>","DOI":"10.1002\/mds.21741","type":"journal-article","created":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T17:47:41Z","timestamp":1192211261000},"page":"2398-2404","source":"Crossref","is-referenced-by-count":195,"title":["Rotigotine transdermal patch in early Parkinson's disease: A randomized, double\u2010blind, controlled study versus placebo and ropinirole"],"prefix":"10.1002","volume":"22","author":[{"given":"Nir","family":"Giladi","sequence":"first","affiliation":[]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[]},{"given":"Amos D.","family":"Korczyn","sequence":"additional","affiliation":[]},{"given":"David J.","family":"Burn","sequence":"additional","affiliation":[]},{"given":"Carl E.","family":"Clarke","sequence":"additional","affiliation":[]},{"given":"Anthony H.V.","family":"Schapira","sequence":"additional","affiliation":[]},{"name":"SP513 investigators","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2007,12,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.393"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.724"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20724"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80109-0"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20602"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.65.2_suppl_1.S3"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1721"},{"key":"e_1_2_7_9_2","first-page":"37","article-title":"Steady\u2010state pharmacokinetics of rotigotine in patients with early\u2010stage Parkinson's disease","volume":"12","author":"Braun M","year":"2005","journal-title":"Eur J Neurol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200105000-00008"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000162228.00154.ba"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2002.01343.x"},{"key":"e_1_2_7_14_2","first-page":"S48","article-title":"Rotigotine transdermal system in patients with advanced\u2010stage Parkinson's disease as adjunctive therapy to levodopa: results of a placebo\u2010 and pramipexole\u2010controlled trial","volume":"21","author":"Poewe W","year":"2006","journal-title":"Mov Disord"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.7.1044"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418110-00003"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00361-8"},{"key":"e_1_2_7_20_2","first-page":"223","article-title":"Contact allergies induced by TTS\u2010treatment","volume":"11","author":"Eichelberg D","year":"1989","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01727445"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1990.tb04774.x"},{"issue":"1","key":"e_1_2_7_23_2","first-page":"369","article-title":"Continuous stimulation of dopamine receptors by continuous delivery of rotigotine in a rat model","volume":"238","author":"Scheller D","year":"2005","journal-title":"J Neurol Sciences"},{"key":"e_1_2_7_24_2","first-page":"37","article-title":"Continuous delivery of rotigotine leads to continuous dopamine receptor stimulation in a rat model","volume":"12","author":"Kehr J","year":"2005","journal-title":"Eur J Neurol"},{"key":"e_1_2_7_25_2","article-title":"Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease","author":"Giladi N","journal-title":"Eur J Neurol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00307-7"},{"key":"e_1_2_7_27_2","first-page":"S68","article-title":"Rotigotine transdermal patch for the treatment of early morning and night time motor symptoms in patients with idiopathic Parkinson\u2032s disease","volume":"22","author":"Giladi N","year":"2007","journal-title":"Mov Disord"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252355.79284.22"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21741","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:25:11Z","timestamp":1760963111000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,15]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2007,12,15]]}},"alternative-id":["10.1002\/mds.21741"],"URL":"https:\/\/doi.org\/10.1002\/mds.21741","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,15]]}}}